In-vitro activity of Sch 34343 against nosocomial pathogens: methicillin-resistant staphylococci, gentamicin-susceptible and -resistant Streptococcus faecalis, Clostridium difficile and Bacteroides fragilis.
The in-vitro activity of Sch 34343, a new beta-lactam antimicrobial, was studied in vitro by quantitative broth dilution methods. It was found to have good antibacterial activity against four emerging problem pathogens: methicillin-resistant Staphylococcus aureus, Streptococcus faecalis isolates showing high level resistance to gentamicin (and other aminoglycosides), Clostridium difficile (the cause of pseudomembranous colitis), and Bacteroides fragilis. On the basis of these promising results, Sch 34343 merits further in-vitro and in-vivo study to define its potential usefulness in treatment of infections with these pathogens in humans.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001441:Bacteroides fragilis / Q000187:drug effects*; D003013:Clostridium / Q000187:drug effects*; D003428:Cross Infection / Q000382:microbiology; D013293:Enterococcus faecalis / Q000187:drug effects*; D005839:Gentamicins / Q000494:pharmacology*; D006801:Humans; D007769:Lactams; D008712:Methicillin / Q000494:pharmacology*; D010403:Penicillin Resistance; D013210:Staphylococcus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007769:Lactams; C044617:Sch 34343; D008712:Methicillin